News Sentiment

CGEN sentiment intelligence

Compugen news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 61 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.01 Week of 19 Jun 2026
Weighted tone 54/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Earnings

75/100 classification confidence.

Company focus 54

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend active

-1.5% over one week, -28.2% over four weeks, trend active, and near fair-value range.

Latest direct headline Neutral

Compugen Ltd (CGEN) Valuation: PE, PB & Fair Value Analysis

Market Reaction

Balanced read

61/100 confidence

News tone and price action are not far from neutral.

Primary event Earnings 75/100 classification
One-week reaction -1.5% Price digesting
Trend fit Trend active -28.2% over four weeks
Fair value 15.9% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 19
Neutral 33
Negative 9

Relevance

Why the article matched

Direct first
Direct company coverage 54
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
Stock Titan 10
TradingKey 8
GuruFocus 4
Moomoo 4
simplywall.st 4
Investing.com 3
TradingView 2

Event Lens

What the news is about

Classified themes
Earnings 27
Market update 18
Analyst action 9
Balance sheet 3
Capital return 1
Macro sensitivity 1
Guidance 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 61
TradingKey Direct company coverage

Compugen Ltd (CGEN) Valuation: PE, PB & Fair Value Analysis

This article analyzes Compugen Ltd's (CGEN) valuation, noting its current valuation score is 7.48, placing it 228th out of 389 in the Biotechnology & Medical Research industry. CGEN's P/E ratio stands at 5.36, significantly below its recent high and above its recent low. However,

Tone
Neutral 50/100
Event
Market update
Published
19 Jun 2026 05:09
Source
TradingKey
TradingKey Direct company coverage

Compugen Ltd (CGEN) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Compugen Ltd (CGEN), detailing its price momentum score of 6.72 and its ranking in the Biotechnology & Medical Research industry. It highlights the stock's current trading range between support at $1.67 and resistance at $2.64, suitab

Tone
Negative 36/100
Event
Market update
Published
18 Jun 2026 17:40
Source
TradingKey
Investing.com Direct company coverage

Compugen presents ovarian cancer trial poster at ESMO meeting

Compugen Ltd. presented a trial-in-progress poster for its MAIA-ovarian adaptive platform trial of COM701 at the ESMO Gynaecological Cancers Congress. The company is evaluating COM701 as a maintenance treatment for relapsed platinum-sensitive ovarian cancer, with initial data exp

Tone
Positive 66/100
Event
Market update
Published
18 Jun 2026 17:09
Source
Investing.com
Stock Titan Direct company coverage

Compugen spotlights COM701 ovarian trial at ESMO congress

Compugen (Nasdaq: CGEN) presented a trial-in-progress poster at the ESMO Gynaecological Cancers Congress 2026 for its MAIA-ovarian adaptive platform trial of COM701. COM701 is a potential first-in-class anti-PVRIG antibody being evaluated as a maintenance treatment for relapsed p

Tone
Positive 70/100
Event
Market update
Published
18 Jun 2026 10:39
Source
Stock Titan
TradingKey Direct company coverage

Compugen Ltd (CGEN) Institutional Confidence

Compugen Ltd (CGEN) has an institutional shareholding score of 3.00, placing it 193rd out of 388 in the Biotechnology & Medical Research industry. The latest institutional shareholding stands at 14.54%, a 16.20% decrease quarter-over-quarter. James Simons is the largest instituti

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 06:39
Source
TradingKey
TradingKey Direct company coverage

Compugen Ltd (CGEN) Financial Health: Profitability & Balance Sheet Analysis

This article analyzes the financial health of Compugen Ltd (CGEN), noting its financial score of 6.25 and ranking in the Biotechnology & Medical Research industry. It highlights the company's robust financial status despite low operating efficiency, with recent quarterly revenue

Tone
Negative 39/100
Event
Earnings
Published
18 Jun 2026 06:09
Source
TradingKey
Market source Direct company coverage

Compugen (CGEN) Stock Faces Mixed Analyst Target Changes After Cautious Valuation Revisions

Compugen (CGEN) is experiencing mixed analyst sentiment, with one firm significantly lowering its price target from US$13 to US$5, while another maintains a fair value estimate at US$4.6. Despite some bullish takes and continued "Outperform" ratings, more cautious voices cite tig

Tone
Neutral 50/100
Event
Analyst action
Published
18 Jun 2026 04:39
Source
Market source
TradingKey Direct company coverage

Compugen Ltd (CGEN) Earnings Forecast: Future EPS & Revenue Growth Estimates

Compugen Ltd (CGEN) has an earnings forecast score of 9.20, ranking 8th in its industry, with analysts assigning a Strong Buy rating and an average price target of $4.00. The company's EPS for the previous quarter was $0.60, significantly exceeding market expectations, and the ne

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 21:39
Source
TradingKey
TradingKey Direct company coverage

Compugen Ltd (CGEN) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Compugen Ltd (CGEN) focusing on its dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no record of stock splits. The page also presents current stock price inform

Tone
Neutral 50/100
Event
Capital return
Published
17 Jun 2026 20:39
Source
TradingKey
Market source Direct company coverage

Compugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026

Compugen Ltd. announced it will present a poster on its MAIA-ovarian Phase 1 study of COM701 at the ESMO Gynaecological Cancers Congress 2026. The poster will detail the adaptive platform clinical trial evaluating the safety and efficacy of COM701 maintenance treatment in relapse

Tone
Positive 66/100
Event
Market update
Published
12 Jun 2026 02:10
Source
Market source
GuruFocus Direct company coverage

Compugen Ltd (CGEN) to Present MAIA-Ovarian Trial Progress at Eu

Compugen Ltd (CGEN) announced it will present progress on its MAIA-ovarian trial at the ESMO Gynecological Cancers Congress in June 2026. GuruFocus rates CGEN as 61.0% undervalued with a GF Value of $5.12, but flags it as a "Possible Value Trap" due to mixed profitability and gro

Tone
Positive 60/100
Event
Macro sensitivity
Published
11 Jun 2026 18:40
Source
GuruFocus
Investing.com Direct company coverage

Compugen to present ovarian cancer trial poster at ESMO

Compugen Ltd. announced it will present a trial-in-progress poster on its MAIA-ovarian Phase 1 study at the ESMO Gynaecological Cancers Congress 2026. The study evaluates COM701 as a maintenance treatment for relapsed platinum-sensitive ovarian cancer. This news follows Compugen'

Tone
Positive 66/100
Event
Market update
Published
11 Jun 2026 15:09
Source
Investing.com
Stock Titan Direct company coverage

AI-driven cancer firm to present ovarian trial at ESMO 2026

Compugen (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company, will present a trial-in-progress poster on its MAIA-ovarian Phase 1 study of COM701 at the ESMO Gynaecological Cancers Congress 2026. The presentation will cover COM701 maintenance treatment in relapsed plati

Tone
Positive 70/100
Event
Market update
Published
11 Jun 2026 10:39
Source
Stock Titan
TradingView Direct company coverage

Compugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug Development

Compugen Ltd. (Nasdaq: CGEN) announced its participation in Jones Trading's "Mapping the Path from Target to Patient: Fireside Chat Series with Leaders in AI/ML-based Drug Development" on Monday, June 15, 2026. The company, a clinical-stage cancer immunotherapy firm leveraging it

Tone
Positive 70/100
Event
Analyst action
Published
08 Jun 2026 11:10
Source
TradingView
Investing.com UK Direct company coverage

H.C. Wainwright reiterates Compugen stock rating on ASCO data

H.C. Wainwright has reiterated its Buy rating and $4.00 price target for Compugen shares (NASDAQ:CGEN) following positive updates on rilvegostomig presented at ASCO, a drug developed in partnership with AstraZeneca. Despite strong clinical data that validates the TIGIT mechanism

Tone
Positive 71/100
Event
Analyst action
Published
04 Jun 2026 13:09
Source
Investing.com UK
Investing.com Canada Direct company coverage

H.C. Wainwright reiterates Compugen stock rating on ASCO data By Investing.com

H.C. Wainwright reiterated a Buy rating and a $4.00 price target for Compugen (NASDAQ: CGEN) following updates on rilvegostomig data presented at the 2026 American Society of Clinical Oncology (ASCO) annual meeting. AstraZeneca, Compugen's partner, provided positive updates on th

Tone
Positive 80/100
Event
Analyst action
Published
04 Jun 2026 11:42
Source
Investing.com Canada
Sahm Direct company coverage

Compugen Q1 2026 Earnings Call: Complete Transcript

Compugen discussed its Q1 2026 financial results, highlighting a strong cash runway extending into 2029 following a $65 million transaction with AstraZeneca. The company is actively enrolling patients for its COM701 clinical program for ovarian cancer, with interim data expected

Tone
Positive 66/100
Event
Earnings
Published
01 Jun 2026 11:09
Source
Sahm
Moomoo Direct company coverage

Earnings Preview: Compugen to Report Financial Results Pre-market on May 18

Compugen Ltd. (NASDAQ: CGEN) is scheduled to release its financial results for the first quarter of 2026 before the market opens on Saturday, May 18, 2026. The company will also host a conference call and live webcast to discuss the results and provide a corporate update. Investo

Tone
Neutral 50/100
Event
Earnings
Published
27 May 2026 23:09
Source
Moomoo
Investing.com Canada Direct company coverage

Compugen Ltd (CGEN) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

Compugen Ltd (CGEN) reported Q1 2026 results highlighting strategic advances in its COM701 clinical program for ovarian cancer and a solid cash runway into 2029. Despite a slight revenue dip and increased R&D expenses leading to a higher net loss, the company emphasized promising

Tone
Neutral 50/100
Event
Earnings
Published
26 May 2026 03:10
Source
Investing.com Canada
Moomoo Direct company coverage

Leerink Partners Maintains Compugen(CGEN.US) With Buy Rating, Cuts Target Price to $5

Leerink Partners has reiterated its Buy rating for Compugen (CGEN.US) but has revised its price target downward to $5. This adjustment reflects an updated outlook from the analytical firm while still signaling confidence in the company's prospects.

Tone
Negative 40/100
Event
Analyst action
Published
22 May 2026 18:09
Source
Moomoo
GuruFocus Direct company coverage

CGEN Maintains Outperform Rating -- Price Target Lowered to $5.0

Leerink Partners has maintained an "Outperform" rating for Compugen (CGEN) but significantly lowered its price target from $13.00 to $5.00, reflecting a reassessment of its market position despite ongoing clinical-stage programs. Although the stock is considered undervalued by Gu

Tone
Negative 39/100
Event
Analyst action
Published
21 May 2026 16:39
Source
GuruFocus
Simply Wall Street Direct company coverage

Compugen (CGEN) Returns To Loss In Q1 2026 And Tests Bullish Profitability Narrative

Compugen (CGEN) reported a loss of US$7.7 million in Q1 2026 with revenue of US$2.2 million, challenging its recent profitability narrative. The majority of its trailing twelve-month revenue was driven by a single large payment in Q4 2025, raising questions about revenue stabilit

Tone
Negative 30/100
Event
Earnings
Published
19 May 2026 22:40
Source
Simply Wall Street
Moomoo Direct company coverage

Press Release: Compugen Reports First Quarter 2026 Results

Compugen has announced its first quarter 2026 financial results. This press release provides an overview of the company's performance during this period, likely including key financial metrics and operational highlights.

Tone
Positive 76/100
Event
Earnings
Published
19 May 2026 21:40
Source
Moomoo
Moomoo Direct company coverage

Earnings Call Summary | Compugen(CGEN.US) Q1 2026 Earnings Conference

This document is an earnings call summary for Compugen (CGEN.US) for their first quarter of 2026. However, no content is provided in the document itself to extract further details about the earnings.

Tone
Neutral 50/100
Event
Earnings
Published
19 May 2026 20:08
Source
Moomoo
TradingView Direct company coverage

CGEN: AI-driven immuno-oncology pipeline advances, with strong partnerships and extended cash runway

Compugen Ltd. (CGEN) is making progress in its AI-driven immuno-oncology pipeline, notably with COM701 for ovarian cancer, and has secured key collaborations with Gilead and AstraZeneca. The company's financial stability, supported by royalty monetization, enables continued inves

Tone
Positive 73/100
Event
Balance sheet
Published
19 May 2026 15:02
Source
TradingView